A PYMNTS Company

US: Parexel exploring a sale

By  |  May 8, 2017

Contract drug research firm Parexel International is exploring a sale, sources familiar with the matter told Reuters on Monday.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Boston-based Parexel had a market value of about $3.51 billion as of Friday’s close. The company’s stock rose as much as 10.2 percent to $75.87 in morning trading.

    The Wall Street Journal reported the talks, saying Parexel is working with investment bankers to sound out potential buyers, including private-equity firms.

    The company did not immediately respond to a request for comment.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.